Dronabinol/palmidrol
pharmaceutical compound
Dronabinol/palmidrol (developmental code names SCI-110, THX-OSA01, THX-RS01, THX-110, and THX-TS01), also known as Δ9-tetrahydrocannabinol/palmitoylethanolamide (THC/PEA), is a combination of dronabinol (Δ9-THC), a cannabinoid CB1 and CB2 receptor agonist, and palmidrol (palmitoylethanolamide; PEA), an endocannabinoid-like fatty acid amide with various cannabidiol (CBD)-like actions, which is under development for the treatment of agitation, Alzheimer's disease, Tourette's syndrome, and sleep apnea syndrome. It was also under development for treatment of back pain, but development for this indication was discontinued. The drug is taken orally. It is thought that palmidrol may enhance the effectiveness and tolerability compared to dronabinol alone. The drug was originated by Therapix Biosciences and is being developed by SciSparc. As of September 2025, the drug is in phase 2 clinical trials for all active indications.
This brief starts where responsible research should: with the source description of “Dronabinol/palmidrol” as pharmaceutical compound. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as pharmaceutical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Aug 29, 2026. The linked authority identifier is Q140246396. The first chronological checks are 2025.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Dronabinol/palmidrol”, its source revision and the description used here.
- Expand the search: follow Dronabinol/palmidrol primary sources, Dronabinol/palmidrol archive and Dronabinol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Dronabinol/palmidrol”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Dronabinol/palmidrol” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.